目的 探讨香丹注射液联合乌拉地尔治疗子痫前期的临床效果。方法 选取2015年1月-2017年12月三门峡市第三人民医院收治的子痫前期患者102例，随机分成对照组（51例）和治疗组（51例）。对照组静脉滴注盐酸乌拉地尔注射液，25 mg加入5%葡萄糖注射液250 mL，起始滴速4~8滴/min，然后根据患者血压调整滴速为10~40滴/min，当舒张压（DBP）维持在90~100 mmHg（1 mmHg=133 Pa）后下调滴速，维持治疗2~4 h，1次/d。治疗组在对照组的基础上静脉滴注香丹注射液，16 mL加入5%葡萄糖注射液250 mL，滴速<60滴/min，1次/d。两组均连续治疗5 d。观察两组患者临床疗效，同时比较治疗前后两组患者血压情况、肾功能、血流变指标、超氧化物歧化酶（SOD）、丙二醛（MDA）、可溶性血管内皮生长因子受体-1（sFlt-1）、胎盘生长因子（PLGF）、血管紧张素Ⅱ（AngⅡ）和AngⅡ1型受体自身抗体（AT1-AA）水平及母婴结局。结果 治疗后，对照组临床有效率为80.4%，显著低于治疗组的94.1%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者收缩压（SBP）值、DBP值、血清尿酸（UA）水平、24 h尿蛋白定量（24 h Upro）值均显著降低（P<0.05），且治疗组血压和肾功能明显优于对照组（P<0.05）。治疗后，两组PV、ESR、EDI值均显著降低（P<0.05），且治疗组血浆黏度（PV）、红细胞沉降率（ESR）和红细胞变形指数（EDI）值明显低于对照组（P<0.05）。治疗后，两组血清SOD、PLGF水平显著升高（P<0.05），MDA、sFlt-1、AngⅡ和AT1-AA水平显著降低（P<0.05），且治疗后治疗组SOD、MDA、sFlt-1、PLGF、AngⅡ和AT1-AA水平明显优于对照组（P<0.05）。治疗后，治疗组终止妊娠时间显著延长、胎盘质量和新生儿体质量均显著增加、1 min Apgar评分显著升高，两组比较差异具有统计学意义（P<0.05）。结论 香丹注射液联合乌拉地尔治疗子痫前期可有效消除患者症状体征，疗效显著，且安全可靠。

Objective To investigate the clinical effect of Xiangdan Injection combined with urapidil in treatment of preeclampsia. Methods Patients (102 cases) with preeclampsia in the Third People's Hospital of Sanmenxia from January 2015 to December 2017 were randomly divided into control (51 cases) and treatment (51 cases) groups. Patients in the control group were iv administered with Urapidil Hydrochloride Injection, 25 mg added into 5% glucose injection 250 mL, the initial dropping speed was 4-8 drops/min and adjusted according to the blood pressure, and the dropping speed range was 10-40 drops/min and decreased when DBP was 90-100 mmHg (1 mmHg=133 Pa), and maintained for 2-4 h, once daily. Patients in the treatment group were iv administered with Xiangdan Injection on the basis of the control group, 16 mL added into 5% glucose injection 250 mL, the dropping speed was less than 60 drops/min, once daily. Patients in two groups were treated for 5 d. After treatment, the clinical efficacy was evaluated, and the blood pressure, the renal function, the hemorheology indexes, SOD, MDA, sFlt-1, PLGF, AngⅡ, AT1-AA, mothers and infants situation in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.4%, which was significantly lower than 94.1% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the SBP, DBP, serum UA concentration, 24 h Upro levels in two groups were significantly decreased (P<0.05), and the blood pressure and the renal function in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the PV, ESR and EDI value in two groups was significantly decreased (P<0.05), and the PV, ESR, and EDI value in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the SOD and PLGF concentration in two groups was significantly increased (P<0.05), MDA, sFlt-1, AngⅡ, and AT1-AA concentration in two groups was significantly decreased (P<0.05), and the SOD, MDA, sFlt-1, PLGF, AngⅡ, and AT1-AA levels in the treatment group were significantly better than those in the control group (P<0.05). After treatment, compared to the control group, the time for termination of pregnancy in the treatment group was significantly prolonged, placental quality, neonatal weight, and 1 min Apgar score was significantly increased, with significant difference between two groups (P<0.05). Conclusion Xiangdan Injection combined with urapidil in treatment of preeclampsia can effectively eliminate the symptoms and signs with remarkable curative effect and high safety.